| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2025 | ESPR Esperion Therapeutics, Inc. | Koenig Sheldon L.63 | President And CEO | Sell | 30,474 | $1.11 | $33,795.67 | -1.9% | +155.0% | +189.0% | |
| Jun 17, 2025 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 17,102 | $59.75 | $1,021,844.50 | -5.8% | -8.9% | -54.7% | |
| Jun 17, 2025 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 240,771 | $57.37 | $13,813,792.08 | -13.9% | -8.9% | -54.7% | |
| Jun 17, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 8,023 | $57.75 | $463,293.80 | -2.4% | -8.9% | -54.7% | |
| Jun 17, 2025 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 8,485 | $59.75 | $506,978.75 | -92.3% | -8.9% | -54.7% | |
| Jun 16, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 17,300 | $28.28 | $489,244.00 | -21.9% | +28.7% | +82.6% | |
| Jun 16, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Patel Gautam | Director | Sell | 94,906 | $8.02 | $761,146.12 | -5.6% | +20.7% | +99.8% | |
| Jun 16, 2025 | CGC Canopy Growth Corp | Hong Judy Eun Joo65 | Chief Financial Officer | Sell | 38,678 | $1.63 | $62,866.33 | -3.2% | -4.1% | -31.0% | |
| Jun 16, 2025 | EOLS Evolus, Inc. | Moatazedi David67 | See Remarks | Sell | 127,905 | $10.03 | $1,283,195.27 | -14.6% | -33.4% | -32.4% | |
| Jun 16, 2025 | CGC Canopy Growth Corp | Gedeon Christelle80 | See Remarks | Sell | 9,555 | $1.47 | $14,045.85 | -2.4% | -4.1% | -31.0% | |
| Jun 16, 2025 | ETON Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | Sell | 34,000 | $14.83 | $504,317.63 | -1.8% | +25.5% | +122.9% | |
| Jun 13, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% Owner | Buy | 5,000 | $0.41 | $2,067.50 | - | - | - | |
| Jun 13, 2025 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 400 | $61.37 | $24,548.00 | -0.5% | +57.8% | +30.6% | |
| Jun 13, 2025 | BHC Bausch Health Companies Inc. | Paulson John68 | Director | Buy | 3,564,059 | $5.94 | $21,170,510.46 | +12.2% | +21.2% | -15.4% | |
| Jun 13, 2025 | LNTH Lantheus Holdings, Inc. | Niedzwiecki Daniel55 | See Remarks | Sell | 6,000 | $78.74 | $472,440.00 | -6.4% | -29.3% | +34.3% | |
| Jun 12, 2025 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 11,000 | $279.96 | $3,079,514.30 | -3.6% | +38.6% | +90.8% | |
| Jun 12, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Sell | 55,775 | $17.08 | $952,464.10 | -12.1% | +10.5% | - | |
| Jun 12, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% Owner | Buy | 70,000 | $0.42 | $29,099.00 | +0.2% | - | - | |
| Jun 12, 2025 | BHC Bausch Health Companies Inc. | Paulson John68 | Director | Buy | 2,788,608 | $5.27 | $14,700,256.94 | +3.4% | +29.8% | - | |
| Jun 11, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% Owner | Buy | 169,600 | $0.40 | $67,991.39 | +0.3% | - | - | |
| Jun 11, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 70,867 | $30.48 | $2,160,035.40 | -24.6% | +22.0% | +70.7% | |
| Jun 11, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Quart Barry D64 | Director | Sell | 27,448 | $30.35 | $833,001.36 | -42.2% | +22.0% | +70.7% | |
| Jun 10, 2025 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 5,600 | $57.00 | $319,200.00 | -2.1% | -10.2% | -49.7% | |
| Jun 10, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Patel Gautam | Director | Sell | 56,426 | $8.02 | $452,536.52 | -3.2% | +24.6% | +96.2% | |
| Jun 10, 2025 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc.60 | 10% Owner | Buy | 7,930 | $15.82 | $125,483.53 | +0.3% | +13.2% | +85.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.